A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies

BACKGROUND: Synergistic cytotoxicity with high-dose statins and erlotinib has been demonstrated in preclinical models across a number of tumour types. In this phase I study, we evaluated the safety and potential anti-tumour activity of escalating doses of rosuvastatin in combination with the standar...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Transl Med
Autors principals: Goss, Glenwood D., Jonker, Derek J., Laurie, Scott A., Weberpals, Johanne I., Oza, Amit M., Spaans, Johanna N., la Porte, Charles, Dimitroulakos, Jim
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4815068/
https://ncbi.nlm.nih.gov/pubmed/27036206
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-016-0836-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars